12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RM-131: Phase II started

Rhythm began a double-blind, placebo-controlled Phase II trial to evaluate 100 µg subcutaneous RM-131 once daily for 14 days in about 48 patients. RM-131 is in...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >